en · de · es · fr · pt
sr9009-notes.peptides6155.com › Faq › Background And Mechanism Of Sr9009 — Explained

Background And Mechanism Of Sr9009 — Explained

By Editorial Desk · published 2025-08-24 · last reviewed 2025-10-04 · Faq

Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-10-04. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Related pages on this site

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

Analytical Detection and Stability

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Supporting material

Between successive cell divisions, cells grow through the functioning of cellular metabolism. Cell metabolism is the process by which individual cells process nutrient molecules. Metabolism has two distinct divisions: catabolism, in which the cell breaks down complex molecules to produce energy and reducing power, and anabolism, in which the cell uses energy and reducing power to construct complex molecules and perform other biological functions. Complex sugars can be broken down into simpler sugar molecules called monosaccharides such as glucose. Once inside the cell, glucose is broken down to make adenosine triphosphate (ATP), a molecule that possesses readily available energy, through two different pathways. In plant cells, chloroplasts create sugars by photosynthesis, using the energy of light to join molecules of water and carbon dioxide.

=== Seasonings === Brining salt (with a larger grain size compared to kitchen salt) is used mainly for initial salting of kimchi vegetables. Being minimally processed, it serves to help develop flavors in fermented foods. Cabbage is usually salted twice when making spicy kimchi. Commonly used seasonings include gochugaru (chili powder), scallions, garlic, ginger, and jeotgal (salted seafood) Jeotgal can be replaced with raw seafood in colder Northern parts of the Korean Peninsula. If used, milder saeu-jeot (salted shrimp) or jogi-jeot (salted croaker) is preferred and the amount of jeotgal is also reduced in Northern and Central regions. In Southern Korea, on the other hand, a generous amount of stronger myeolchi-jeot (salted anchovies) and galchi-jeot (salted hairtail) is commonly used. Raw seafood or daegu-agami-jeot (salted cod gills) are used in the East coast areas. Salt, scallions, garlic, fish sauce, and sugar are commonly added to flavor the kimchi.

About 100,000 protesters occupied Piața Operei (Opera Square – today Piața Victoriei, Victory Square) and chanted anti-government slogans: "Noi suntem poporul!" ("We are the people!"), "Armata e cu noi!" ("The army is on our side!"), "Nu vă fie frică, Ceaușescu pică!" ("Have no fear, Ceaușescu is falling!") Meanwhile, Secretary to the Central Committee Emil Bobu and Prime Minister Constantin Dăscălescu were sent by Elena Ceaușescu (Nicolae being at that time in Iran) to resolve the situation. They met with a delegation of the protesters and agreed to free the majority of the arrested protesters. However, they refused to comply with the protesters' main demand— the resignation of Ceaușescu—and the situation remained essentially unchanged. The next day, trains loaded with workers from factories in Oltenia arrived in Timișoara. The regime was attempting to use them to repress the mass protests, but after a brief encounter they ended up joining the protests. One worker explained, "Yesterday our factory boss and a party official rounded us up in the yard, handed us wooden clubs and told us that Hungarians and 'hooligans' were devastating Timișoara and that it is our duty to go there and help crush the riots.

=== Open-chain form === An open-chain form of glucose makes up less than 0.02% of the glucose molecules in an aqueous solution at equilibrium. The rest is one of two cyclic hemiacetal forms. In its open-chain form, the glucose molecule has an open (as opposed to cyclic) unbranched backbone of six carbon atoms, where C-1 is part of an aldehyde group H(C=O)−. Therefore, glucose is also classified as an aldose, or an aldohexose. The aldehyde group makes glucose a reducing sugar giving a positive reaction with the Fehling test.

Sources: en.wikipedia.org

Notes from published material

=== 17 March === The United Nations said the RSF detained more than 60 peacekeepers, abducted eight civilian staff, and seized eight vehicles and 280,000 litres of fuel from a United Nations Interim Security Force for Abyei (UNISFA) logistics convoy heading from a refueling mission in Kadugli.

Sasaki laboratory and others of the kind, the multi-million dollar cost of such laboratories has prevented adoption by smaller groups. This is all more difficult because devices made by different manufactures often cannot communicate with each other. However, recent advances based on the use of scripting languages like Autoit have made possible the integration of equipment from different manufacturers. Using this approach, many low-cost electronic devices, including open-source devices, become compatible with common laboratory instruments. Some startups such as Emerald Cloud Lab and Strateos provide on-demand and remote laboratory access on a commercial scale. A 2017 study indicates that these commercial-scale, fully integrated automated laboratories can improve reproducibility and transparency in basic biomedical experiments, and that over nine in ten biomedical papers use methods currently available through these groups.

While both members bear S-glycosyl groups, RiPPs bearing O- or N-linked carbohydrates will also be included in this family as they are discovered. Linaridins are characterized by C-terminal aminovinyl cysteine residues. While this posttranslational modification is also seen in the lanthipeptides epidermin and mersacidin, linaridins do not have Lan or MeLan residues. In addition, the linaridin moiety is formed from modification of two Cys residues, whereas lanthipeptide aminovinyl cysteines are formed from Cys and dehydroalanine (Dha). The first linaridin to be characterized was cypemycin. Microviridins are cyclic N-acetylated trideca- and tetradecapeptides with ω-ester and/or ω-amide bonds. Lactone formation through glutamate or aspartate ω-carboxy groups and the lysine ε-amino group forms macrocycles in the final natural product. This class of RiPPs function as protease inhibitors and were originally isolated from Microcystis viridis. Gene clusters encoding microviridins have also been identified in genomes across the Bacteroidetes and Proteobacteria phyla. Orbitides are plant-derived N-to-C cyclized peptides with no disulfide bonds. Also referred to as Caryophyllaceae-like homomonocyclopeptides, orbitides are 5-12 amino acids in length and are composed of mainly hydrophobic residues. Similar to the amatoxins and phallotoxins, the gene sequences of orbitides suggest the presence of a C-terminal recognition sequence.

Sources: en.wikipedia.org

Further detail

[We] have to act according not only to the facts but to the ... evidence. I am sure you understand that these are very grave accusations." The European Ombudsman, Emily O'Reilly, was, however critical of the response of Von der Leyen and fellow politicians and institutions, highlighting the lack of progress shown by von der Leyen following her pledge that transparency would be a core part of her mandate when she became European Commission President. O'Reilly called for a body to be created with real investigatory and sanctions powers. The Belgian Prime Minister, Alexander De Croo, was also critical of the European institutions in his response, stating that "Belgian justice is doing what, at first sight, the European Parliament hasn't done." "The European Parliament has a lot of means to regulate itself. It turns out that this is largely a system of auto-control based on voluntary efforts, which has clearly not been sufficient." Annalena Baerbock, the German Minister for Foreign Affairs, highlighted that the scandal is leading to concerns from citizens and affects the credibility and legitimacy of the institutions of the European Union. On 15 December the European People's Party (EPP) reacted by declaring, "We need to discuss hypocrisy ... This is an S&D scandal." In an attempt to focus the scandal on the Progressive Alliance of Socialists and Democrats Group (S&D), rather than the European Parliament as a whole, they continued, "There has been a consistent effort to turn #Qatargate into an institutional issue alone. But this scandal is not an orphan. ... It has an address.

=== The 12 nidānas as an early list === Against the view that the 12 link chain is later, Alex Wayman writes "I am convinced that the full twelve members have been in Buddhism since earliest times, just as it is certain that a natural division into the first seven and last five was also known." Bhikkhu Bodhi writes that the suggestions of some scholars the twelvefold formula is a later expansion of a shorter list "remain purely conjectural, misleading, and objectionable on doctrinal and textual grounds." Choong, in his comparative study of SN and SA also writes that the different accounts of dependent origination existed at an early stage and that they are simply different ways of presenting the same teaching which would have been used for different times and with audiences. Choong writes that the various versions of dependent arising "are unlikely to represent a progressive development, with some being earlier and others later" and that "the comparative data revealed here do not provide evidence to support the speculative suggestion that there was just one original (or relatively early) account of the series, from which the other attested accounts developed later."

== Comparison with TARS3 == Cytoplasmic threonine–tRNA ligase is unique in vertebrate aminoacyl-tRNA synthetases in having a second form, TARS3 (previously called TARSL2), evolved from a gene duplication. In mice, the TARS1 enzyme is significantly more prevalent (55x in lungs, and 3x in muscles). Structurally, TARS1 functions as a homodimer, while TARS3 may instead be a component of the protein complex: multisynthetase complex (MSC). TARS1 is also smaller, 83 kD vs. 93 kD, and this has been used to infer that it is the primary target of the antibodies involved in antisynthetase syndrome.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

How is SR9009 usually analyzed?

Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.

Network